China National Accord Medicines (000028.SZ) Earnings Analysis

China National Accord Medicines (000028.SZ) next reports earnings on 2026-08-29, consensus EPS 0.53 CNY. Last quarter (2026-03-17) it missed with EPS 0.29 CNY vs 0.4182 CNY est (-30.7%). It has beaten estimates in 3/7 recent quarters (43%). Trailing P/E 10.46.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 000028.SZ next report earnings?

Next earnings date2026-08-29
Consensus EPS estimate0.53 CNY
Revenue estimate20.00B

000028.SZ earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-170.29 CNY0.4182 CNY-30.7%Miss
2025-10-210.4727 CNY0.555 CNY-14.8%Miss
2025-08-140.61 CNY0.509 CNY+19.8%Beat
2025-04-250.59 CNY0.555 CNY+6.3%Beat
2025-03-18-0.76 CNY0.609 CNY-224.8%Miss
2024-10-280.57 CNY0.62 CNY-8.1%Miss
2024-08-280.64 CNY0.63 CNY+1.6%Beat

Beat rate: 3/7 (43%) over reported quarters with consensus data.

000028.SZ valuation and analyst view

Trailing P/E10.46
Trailing EPS1.981 CNY
Price / book0.60
Dividend yield2.99%
Market cap11.00B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is China National Accord Medicines (000028.SZ)'s next earnings date?

China National Accord Medicines is next scheduled to report on 2026-08-29, with a consensus EPS estimate of 0.53 CNY and revenue estimate of 20.00B.

Did 000028.SZ beat earnings last quarter?

In its 2026-03-17 report, 000028.SZ posted EPS of 0.29 CNY versus a 0.4182 CNY estimate — a miss of 30.7%.

What is 000028.SZ's earnings track record?

Over the last 7 reported quarters with consensus data, 000028.SZ beat estimates 3 times (43%).

What is 000028.SZ's current P/E ratio and EPS?

000028.SZ trades at a trailing P/E of 10.46 on trailing EPS of 1.98148531601102 CNY.

What do analysts rate 000028.SZ?

000028.SZ has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.